The Economics of Prostate Cancer Screening

ONCOLOGY

Volumn 11, Issue 10, 1997, Pages 1533-1543

  Benoit, Ronald M ^a   Naslund, Michael J ^b,c  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b Division of Urology   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

COST BENEFIT ANALYSIS; COST CONTROL; ECONOMICS; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MALE; MASS SCREENING; PROSTATE TUMOR; QUALITY OF LIFE; REVIEW;

COST CONTROL; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; MALE; MASS SCREENING; PROGRAM EVALUATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 0031242675     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948, 1993.
2. Benoit RM, Naslund MJ: Detection of latent prostate cancer from routine screening: comparison with breast cancer screening. Urology 46:533, 1995.
3. Jacobsen SJ, Katusic SK, Bergstrath EJ, et al: Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA 274:1445, 1995.
4. Optenberg SA, Thompson IM: Economics of screening for carcinoma of the prostate. Urol Clin North Am 17:719, 1990.
5. Kramer BS, Brown ML, Prorok PC, et al: Prostate cancer screening: what we know and what we need to know. Ann Intern Med 119:914, 1993.
6. Mammography and clinical breast exams among women aged 50 years and older - Behavioral Risk Factor Surveillance System, 1992. Morbid Mortal Weekly Rep 42:737, 1993.
7. Richie JP, Catalona WJ, Ahmann F, et al: Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology 42: 365, 1993.
8. Benoit RM, Naslund MJ: A quantitative analysis of the cost per life year saved for prostate cancer screening and treatment. J Urol 155:564A, 1996.
9. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA 267 2215, 1992.
10. Jones GW, Mettlin C, Murphy GP, et al: Patterns of care for carcinoma of the prostate gland: Results of a national survey of 1984 and 1990. J Am Coll Surg 180:545, 1995.
11. Krahn MD, Mahoney JE, Eckman MH, et al: Screening for prostate cancer: a decision analytical view JAMA 272:773, 1994.
12. Chodak GW, Keller P, Schoenberg HW: Assessment of screening for prostate cancer using the digital rectal examination. J Urol 141:1136, 1989.
13. Fleming C, Wasson JH, Albertsen PC, et al: A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA 269:2650, 1993.
14. Johansson J-E, Adami H-O, Andersson S-O, et al: High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 167:2191, 1992.
15. Chodak GW, Steinberg GD, Bibbo M, et al: The role of transrectal aspiration biopsy in the diagnosis of prostatic cancer. J Urol 135:299, 1986
16. Beck JR, Kattan MW, Miles BJ: A critique of the decision analysis for clinically localized prostate cancer. J Urol 152:1894, 1994.
17. Chodak GW, Trusted RA, Gerber GS, et al: Results of conservative management of clinically localized prostate cancer. New Engl J Med 330:242.1994
18. Rosen MA: Impact of prostate-specific antigen screening on the natural history of prostate cancer. Urology 46:757, 1995.
19. Jewett HJ, Bridge RW, Gray GF, et al: The palpable nodule of prostatic cancer: results 15 years after radical excision. JAMA 203:115, 1968.
20. Myers RP, Fleming TR: Course of localized adenocarcinoma of the prostate treated by radical prostatectomy. Prostate 4:461, 1983.
21. Paulson DF, Moul JW, Walther PJ: Radical prostatectomy for clinical stage T1-2NOMO: long term results. J Urol 144:1180, 1990.
22. Gronberg H, Damber J-E, Jonnson J, et al: Patient age as a prognositic factor in prostate cancer. Urol 152:892, 1994.
23. Albertsen PC, Fryback DG, Storer BE, et al: Long term survival among men with conservatively treated localized prostate cancer. JAMA 274:626, 1995.
24. Cummings SR, Rubin SM, Oster G: The cost effectiveness of counseling smokers to quit. JAMA 261:75, 1989.
25. Mushlin AI, Fintor L: Is screening for breast cancer cost-effective? Cancer 69:1957, 1992.
26. Garner TI, Dardis R: Cost-effectiveness analysis of end-stage renal disease treatments. Med Care 255:25, 1987.
27. Fabs MC, Mandelblatt J, Schechter C, et al: Cost effectiveness of cervical cancer screening for the elderly. Ann Intern Med 117:520, 1992.
28. Byers T, Gorsky R: Estimates of costs and effects of screening for colorectal cancer in the United States. Cancer 70:1288, 1992.